Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
29.74
-0.45 (-1.49%)
At close: Oct 7, 2025, 4:00 PM EDT
29.75
+0.01 (0.03%)
After-hours: Oct 7, 2025, 7:57 PM EDT

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
North America Revenue
354.61M340.46M
Log In
Log In
Log In
Upgrade
Latin America Revenue
144.46M130.71M
Log In
Log In
Log In
Upgrade
Europe Revenue
97.72M80.12M
Log In
Log In
Log In
Upgrade
Asia-Pacific Revenue
13.36M8.93M
Log In
Log In
Log In
Upgrade
Revenue (Total)
610.16M560.23M
Log In
Log In
Log In
Upgrade

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
Crysvita Revenue
147.83M134.71M
Log In
Log In
Log In
Upgrade
Dojolvi Revenue
92.69M88.19M
Log In
Log In
Log In
Upgrade
Evkeeza Revenue
46.64M32.16M
Log In
Log In
Log In
Upgrade
Mepsevii Revenue
34.29M30.35M
Log In
Log In
Log In
Upgrade
Total Product Revenue
321.45M285.42M
Log In
Log In
Log In
Upgrade
Crysvita Royalty Revenue
288.71M274.82M
Log In
Log In
Log In
Upgrade
Crysvita Collaboration Revenue in Profit-Share Territory
--
Log In
Log In
Log In
Upgrade
Crysvita Royalty Revenue in European Territory
--
Log In
Log In
Log In
Upgrade
Daiichi Sankyo Revenue
--
Log In
Log In
Log In
Upgrade
Total Collaboration and License Revenue
--
Log In
Log In
Log In
Upgrade
Revenue (Other)
-46.64M-32.16M
Log In
Log In
Log In
Upgrade
Revenue (Total)
610.16M560.23M
Log In
Log In
Log In
Upgrade
Updated Aug 5, 2025. Data Source: Fiscal.ai.